Upgrade to SI Premium - Free Trial

Jaguar Health (JAGX)

2.80 -0.25 (8.20%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/19/26)

Latest Headlines

Form 8-K Jaguar Health, Inc. For: Jun 01 June 2, 2026 4:10 PM - SEC Filing Form DEFA14A Jaguar Health, Inc. May 29, 2026 5:24 PM - SEC Filing Jaguar Health advances crofelemer development for rare gastrointestinal disorders May 28, 2026 10:02 AM - StreetInsider Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders May 28, 2026 10:00 AM - StreetInsider Form 8-K Jaguar Health, Inc. For: May 26 May 27, 2026 9:10 AM - SEC Filing Jaguar Health regains compliance with NASDAQ bid price rule May 27, 2026 9:01 AM - StreetInsider Jaguar Health Compliant with Nasdaq Bid Price Rule May 27, 2026 9:01 AM - StreetInsider Form 8-K Jaguar Health, Inc. For: May 21 May 22, 2026 5:23 PM - SEC Filing Jaguar Health (JAGX) Misses Q1 EPS by 1360c May 21, 2026 11:10 AM - StreetInsider Jaguar Health Reports First Quarter 2026 Financials May 20, 2026 4:40 PM - StreetInsider Form 8-K Jaguar Health, Inc. For: May 20 May 20, 2026 4:36 PM - SEC Filing Form 10-Q Jaguar Health, Inc. For: Mar 31 May 20, 2026 4:07 PM - SEC Filing Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference May 20, 2026 9:04 AM - StreetInsider Form 8-K Jaguar Health, Inc. For: May 19 May 19, 2026 5:07 PM - SEC Filing Jaguar Health advances MVID drug trial to extension phase May 19, 2026 9:04 AM - StreetInsider Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) May 19, 2026 9:02 AM - StreetInsider Form NT 10-Q Jaguar Health, Inc. For: Mar 31 May 18, 2026 3:06 PM - SEC Filing Jaguar Health regains NASDAQ compliance, gets extension to meet bid price rule May 8, 2026 9:01 AM - StreetInsider Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule May 8, 2026 9:01 AM - StreetInsider Form 8-K Jaguar Health, Inc. For: May 06 May 7, 2026 2:59 PM - SEC Filing Jaguar Health discusses FDA breakthrough therapy designation for rare disease treatment May 6, 2026 9:01 AM - StreetInsider Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID) May 6, 2026 9:00 AM - StreetInsider Form DEFA14A Jaguar Health, Inc. May 6, 2026 8:00 AM - SEC Filing Form 8-K Jaguar Health, Inc. For: May 04 May 4, 2026 5:10 PM - SEC Filing Jaguar Health launches Neonorm Dog for canine digestive health May 4, 2026 8:31 AM - StreetInsider Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health May 4, 2026 8:30 AM - StreetInsider Form 8-K Jaguar Health, Inc. For: May 01 May 4, 2026 8:00 AM - SEC Filing Form DEF 14A Jaguar Health, Inc. For: May 22 April 30, 2026 10:13 AM - SEC Filing Form ARS Jaguar Health, Inc. For: Dec 31 April 30, 2026 6:06 AM - SEC Filing Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs April 29, 2026 8:36 AM - StreetInsider Form 8-K Jaguar Health, Inc. For: Apr 24 April 27, 2026 9:10 AM - SEC Filing Jaguar Health gets nasdaq extension, plans 1-for-35 reverse stock split April 27, 2026 9:08 AM - StreetInsider Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split April 27, 2026 9:07 AM - StreetInsider Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterolog April 24, 2026 8:35 AM - StreetInsider Form PRE 14A Jaguar Health, Inc. For: May 22 April 21, 2026 8:22 AM - SEC Filing Form 8-K Jaguar Health, Inc. For: Apr 20 April 21, 2026 7:35 AM - SEC Filing Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders April 20, 2026 4:15 PM - StreetInsider Jaguar Health plans AI integration for rare disease drug development April 13, 2026 8:32 AM - StreetInsider Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs April 13, 2026 8:31 AM - StreetInsider Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates April 9, 2026 8:17 PM - StreetInsider Form 8-K Jaguar Health, Inc. For: Apr 07 April 9, 2026 5:05 PM - SEC Filing Jaguar Health completes dog diarrhea drug effectiveness trial April 8, 2026 8:32 AM - StreetInsider Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs April 8, 2026 8:30 AM - StreetInsider Form S-8 Jaguar Health, Inc. April 7, 2026 5:11 PM - SEC Filing Form 8-K Jaguar Health, Inc. For: Apr 07 April 7, 2026 12:54 PM - SEC Filing Form 10-K Jaguar Health, Inc. For: Dec 31 April 7, 2026 12:40 PM - SEC Filing Jaguar Health Reports 2025 Financials April 7, 2026 8:41 AM - StreetInsider Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress April 2, 2026 9:00 AM - StreetInsider Form NT 10-K Jaguar Health, Inc. For: Dec 31 April 1, 2026 4:19 PM - SEC Filing Form DEF 14A Jaguar Health, Inc. For: Apr 20 March 24, 2026 5:06 PM - SEC Filing Jaguar Health receives FDA support for MVID trial extension phase March 18, 2026 9:01 AM - StreetInsider FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID) March 18, 2026 9:01 AM - StreetInsider Magdalena Biosciences begins preclinical study of coca for appetite control March 16, 2026 9:00 AM - StreetInsider Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression March 16, 2026 9:00 AM - StreetInsider Form PRE 14A Jaguar Health, Inc. For: Apr 20 March 13, 2026 5:00 PM - SEC Filing Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing March 13, 2026 8:35 AM - StreetInsider Form 4 Jaguar Health, Inc. For: Dec 11 Filed by: MICEK JOHN March 12, 2026 3:04 PM - SEC Filing Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts March 11, 2026 9:01 AM - StreetInsider Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th March 10, 2026 10:22 AM - StreetInsider Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th March 10, 2026 10:21 AM - Globe NewsWire Form 8-K Jaguar Health, Inc. For: Mar 06 March 9, 2026 9:07 AM - SEC Filing Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants March 9, 2026 9:01 AM - StreetInsider Full Article List